利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

70 条记录 (耗时 0.022 秒)

    Anti-CD3epsilon antibodies
    51.
    发明授权
    Anti-CD3epsilon antibodies 有权

    公开(公告)号：US11440962B2

    公开(公告)日：2022-09-13

    申请号：US16649149

    申请日：2018-09-20

    申请人： WuXi Biologics Ireland Limited

    发明人： Jing Li ,  Qin Mei

    IPC分类号： C07K16/28 ,  A61K47/68

    摘要： The present disclosure provides isolated monoclonal anti-CD3epsilon antibodies or antigen-binding fragments thereof comprising one or more heavy chain CDR sequences selected from the group consisting of: SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, and 47, and/or one or more kappa light chain CDR sequences selected from the group consisting of: SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46 and 48, isolated polynucleotides encoding the same, pharmaceutical compositions comprising the same, and the use thereof.

    ANTI-TIM-3 ANTIBODIES AND USES THEREOF
    52.
    发明申请
    ANTI-TIM-3 ANTIBODIES AND USES THEREOF 有权

    公开(公告)号：US20210340252A1

    公开(公告)日：2021-11-04

    申请号：US17312847

    申请日：2019-12-11

    申请人： WUXI BIOLOGICS IRELAND LIMITED

    发明人： Siwei NIE ,  Yong ZHENG ,  Jun PAN ,  Jianqing XU ,  Jing LI

    IPC分类号： C07K16/28 ,  A61P35/00

    摘要： Provided in the present disclosure are anti-TIM-3 antibodies, the methods of hybridoma generation, the nucleic acid molecules encoding the anti-TIM-3 antibodies, expression vectors and host cells used for the expression of anti-TIM-3 antibodies. The disclosure further provides the methods for validating the function of antibodies in vitro and the efficacy of antibodies in vivo. The antibodies of the disclosure provide a very potent agent for the treatment of cancers via modulating immune functions.

    Anti-PD-1 antibodies
    54.
    发明授权
    Anti-PD-1 antibodies 有权

    公开(公告)号：US11008391B2

    公开(公告)日：2021-05-18

    申请号：US15751236

    申请日：2016-08-11

    申请人： WuXi Biologics Ireland Limited

    发明人： Yong Zheng ,  Jing Li ,  Zhisheng Chen

    IPC分类号： C07K16/28

    摘要： The present disclosure provides monoclonal antibodies against protein programmed cell death 1 (PD-1), which can block the binding of PD-1 ligands to PD-1, and therefore block the inhibitory function of PD-1 ligands on PD-1 expressing T cells. The antibodies of disclosure provide very potent agents for the treatment of multiple cancers via modulating human immune function.

    NOVEL BISPECIFIC CD3/CD19 POLYPEPTIDE COMPLEXES
    55.
    发明申请
    NOVEL BISPECIFIC CD3/CD19 POLYPEPTIDE COMPLEXES 审中-公开

    公开(公告)号：US20200283523A1

    公开(公告)日：2020-09-10

    申请号：US16648792

    申请日：2018-09-20

    申请人： WUXI BIOLOGICS IRELAND LIMITED

    发明人： Jieying LIU ,  Jianqing XU ,  Zhuozhi WANG ,  Qin MEI ,  Jing LI

    IPC分类号： C07K16/28 ,  C12N15/63 ,  A61P35/00 ,  G01N33/68

    摘要： A bispecific anti-CD3×CD19 polypeptide complex that contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety, methods of producing the bispecific anti-CD3×CD19 polypeptide complex, methods of treating disease or disorder using the bispecific anti-CD3×CD19 polypeptide complex, polynucleotides encoding the bispecific anti-CD3×CD19 polypeptide complex, vectors and host cells containing said polynucleotides, and compositions and pharmaceutical compositions comprising the bispecific anti-CD3×CD19 polypeptide complex are provided.

    INTELLIGENT SYSTEM FOR GENE SYNTHESIS AND MONOCLONAL PICKING
    56.
    发明公开
    INTELLIGENT SYSTEM FOR GENE SYNTHESIS AND MONOCLONAL PICKING 审中-公开

    公开(公告)号：US20240344015A1

    公开(公告)日：2024-10-17

    申请号：US18708515

    申请日：2022-11-11

    申请人： INNOVEL INTELLIGENT TECHNOLOGY CO., LTD. ,  WUXI BIOLOGICS IRELAND LIMITED

    发明人： Hao CHEN ,  Kailin YANG ,  Yan ZHI ,  Xiaoyue CHEN

    IPC分类号： C12M1/36 ,  C12M1/00 ,  C12M1/26 ,  C12M1/34

    CPC分类号： C12M41/48 ,  C12M29/06 ,  C12M33/04 ,  C12M41/12 ,  C12M41/46 ,  C12M47/10

    摘要： An intelligent system for gene synthesis and monoclonal picking, comprising: a core operation module for performing operations associated with gene synthesis and monoclonal picking; and a control system for controlling at least a part of operations of corresponding compartments of the core operation module. The core operation module at least includes: a liquid operation compartment for performing operations of mixing gene fragments and mixing synthetizing reagents with biological samples in the process of gene synthesis; a purification compartment for performing purification operations on nucleic acid products created after the mixing; an amplification compartment for performing amplification operations and error correction operations on fragments of the nucleic acid products and performing culturing and amplification operations on vectors; and a monoclonal picking compartment for performing monoclonal picking operations on purified and cultured nucleic acid products.

    NOVEL BISPECIFIC POLYPEPTIDE COMPLEXES
    59.
    发明公开
    NOVEL BISPECIFIC POLYPEPTIDE COMPLEXES 审中-公开

    公开(公告)号：US20240124586A1

    公开(公告)日：2024-04-18

    申请号：US18480252

    申请日：2023-10-03

    申请人： WUXI BIOLOGICS IRELAND LIMITED

    发明人： Jianqing XU ,  Zhuozhi WANG ,  Jing LI

    IPC分类号： C07K16/28 ,  C12N15/63

    CPC分类号： C07K16/2809 ,  C12N15/63 ,  A61K2039/505

    摘要： A polypeptide complex comprises antibody variable regions of the heavy chain and light chain respectively fused to TCR constant regions. A bispecific antigen binding polypeptide complex contains a first antigen-binding moiety of the polypeptide complex and a second antigen-binding moiety. A method comprises producing the polypeptide complex of the bispecific antigen binding polypeptide complex. A method of treating disease or disorder comprises using the polypeptide complex or the bispecific antigen binding polypeptide complex. A polynucleotide encodes the polypeptide complex and/or the bispecific antigen binding polypeptide complex. A vector or a host cell contains the polynucleotide. A composition and a pharmaceutical composition comprise the polypeptide complex and/or the bispecific antigen binding polypeptide complex.